Combined Ketamine and Psychotherapy Provide No Additional Benefit Beyond Ketamine Alone in Treating Depression or PTSD: Evidence from a Help-Seeking Sample

Adding psychotherapy to ketamine treatment does not significantly improve depression or PTSD symptoms more than ketamine alone over 30 days. Both approaches produced substantial, rapid symptom improvement that stabilized after 11-15 days. The study analyzed 202 help-seeking individuals (60% female, mean age 41.3 years) who received either ketamine alone or ketamine plus psychotherapy across six sessions. No significant differences in symptom trajectories emerged between the groups, though exploratory analyses suggested younger females might benefit more from combined treatment and older males from ketamine alone. The findings indicate ketamine's effects may be robust enough that concurrent psychotherapy does not enhance short-term outcomes, but longer-term and demographic-specific effects require further study.

Study at a glance

Abstract

Depression and PTSD are prevalent psychiatric conditions that often co-occur and significantly impact quality of life. Ketamine has emerged as a promising rapid-acting treatment for both conditions, while traditional treatments like psychotherapy typically require weeks to show effects. This study investigated whether combining ketamine with psychotherapy produces greater symptom improvement compared to ketamine alone. We analyzed data from 202 help-seeking individuals (60% female, mean age 41.3 years) who received either ketamine alone (KET) or ketamine plus psychotherapy (KET+PSY) across six treatment sessions within a 30-day period. Depression symptoms were measured using the PHQ-9, and PTSD symptoms were assessed using the PCL-5. Trajectories of symptom change were analyzed using generalized additive mixed-effects models, controlling for baseline symptoms, demographics, and treatment intervals. Both treatment groups showed substantial improvement in depression and PTSD symptoms, with similar patterns of rapid initial decline followed by stabilization around 11-15 days. Contrary to our hypothesis, we found no significant differences in symptom trajectories between the KET and KET+PSY groups. Exploratory analyses revealed non-significant but notable patterns where younger females showed better outcomes with combined treatment, while older males showed better outcomes with ketamine alone. These findings suggest that ketamine's therapeutic effects may be robust enough that additional psychotherapy during the acute treatment phase does not significantly enhance 30-day outcomes. However, longer-term benefits of combined treatment and potential demographic-specific treatment responses warrant further investigation. These results have important implications for treatment planning and resource allocation in clinical settings.